2023
DOI: 10.1002/clc.24021
|View full text |Cite
|
Sign up to set email alerts
|

For patients with prior coronary artery bypass grafting and recurrent myocardial ischemia, percutaneous coronary intervention on bypass graft or native coronary artery?—A 5‐year follow‐up cohort study

Abstract: Background: Real-world data on target vessel of percutaneous coronary intervention (PCI) for patients with prior coronary artery bypass grafting (CABG) was still limited.Hypothesis: A prospective cohort was examined to determine the frequency and outcomes of native coronary artery PCI versus bypass graft PCI in patients with prior CABG.Methods: A large-sample observational study enrolled a total of 10 724 patients with coronary artery disease (CAD) underwent PCI in 2013. Two-and five-year clinical outcomes wer… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 29 publications
0
1
0
Order By: Relevance
“…However, reperfusion can further damage the ischemic myocardium, referred to as myocardial ischemia/reperfusion injury (MIRI) ( 5 ), which can affect the prognosis of patients. Currently, the main clinical treatment for myocardial ischemia is percutaneous artery intervention (PCI), however, this treatment only provides short-term relief and also leads to myocardial re-damage ( 6 ). Other current treatments, such as calcium channel blockers or hypoxia preconditioning, are used for MIRI but are not very effective, as multiple factors are involved in the pathophysiological process of MIRI ( 7 , 8 ), there is an urgent requirement to find more therapeutic solutions for MIRI.…”
Section: Introductionmentioning
confidence: 99%
“…However, reperfusion can further damage the ischemic myocardium, referred to as myocardial ischemia/reperfusion injury (MIRI) ( 5 ), which can affect the prognosis of patients. Currently, the main clinical treatment for myocardial ischemia is percutaneous artery intervention (PCI), however, this treatment only provides short-term relief and also leads to myocardial re-damage ( 6 ). Other current treatments, such as calcium channel blockers or hypoxia preconditioning, are used for MIRI but are not very effective, as multiple factors are involved in the pathophysiological process of MIRI ( 7 , 8 ), there is an urgent requirement to find more therapeutic solutions for MIRI.…”
Section: Introductionmentioning
confidence: 99%